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ABSTRACT
Tumor-initiating cells (TICs) play important roles in tumor progression and
metastasis. Identifying the factors regulating TICs may open new avenues in cancer
therapy. Here, we show that TIC-enriched prostate cancer cell clones use more
glucose and secrete more lactate than TIC-low clones. We determined that elevated
levels of phosphoenolpyruvate carboxykinase isoform 2 (PCK2) are critical for the
metabolic switch and the maintenance of TICs in prostate cancer. Information from
prostate cancer patient databases revealed that higher PCK2 levels correlated with
more aggressive tumors and lower survival rates. PCK2 knockdown resulted in low
TIC numbers, increased cytosolic acetyl-CoA and cellular protein acetylation. Our
data suggest PCK2 promotes tumor initiation by lowering acetyl-CoA level through
reducing the mitochondrial tricarboxylic acid (TCA) cycle. Thus, PCK2 is a potential
therapeutic target for aggressive prostate tumors.

that a single switch to the embryonic isoform of pyruvate
kinase (PKM2) is necessary for the shift from OXPHOS
to glycolysis in cancer cells and that this switch promotes
tumorigenesis [6, 7]. The enhanced glycolysis in cancer cells
can decrease reactive oxygen species (ROS), and promote
the pentose phosphate pathway (PPP) and serine/glycine
synthesis pathway, which are both linked to tumorigenesis
[8–11].
In addition, yeast and many mammalian cells rely
on acetyl-CoA for growth [12–15]. Acetyl-CoA is an
essential building block for synthesis of fatty acids or
sterols, or for the acetylation of histones on a set of more
than 1,000 genes critical for cell growth [12]. In well-fed
mammalian cells, the acetyl-CoA is primarily supplied
by converting mitochondrial derived citrate into acetylCoA via ATP citrate lyase (ACLY) [16, 17]. In highly
glycolytic or hypoxic tumors, glucose-derived pyruvate is
preferentially shunted toward lactate instead of entering
into the mitochondrial tricarboxylic acid (TCA) cycle
for production of citrate and acetyl-CoA. It was recently

INTRODUCTION
Emerging data suggest that a subpopulation of
self-renewing and evolving tumor-initiating cells (TICs),
popularly known as cancer stem cells (CSCs), may be
responsible for tumor metastasis, and patient relapse and
death [1]. Although the biological and clinical relevance
of TICs/CSCs remains controversial, most solid tumors,
including prostate cancer tumors, appear to follow the TIC/
CSC model [2]. TICs are resistant to both radiation and
chemotherapy in conventional treatments [3, 4]. Moreover,
such treatments enrich TICs in tumors, endowing them
with more aggressive characteristics. Unfortunately, there
are no obvious molecular targets for TICs in rational drug
design, because the molecular pathways underlying TIC
maintenance are not well understood.
More than 75 years ago, Otto Warburg observed
that tumor cells, like embryonic cells, preferentially use
glycolysis to convert glucose carbon to lactate, even under
aerobic conditions [5]. More recently, reports have shown
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reported that the nucleocytosolic acetyl-CoA synthetase
enzyme, ACSS2, converts acetate into a key source of
acetyl-CoA for tumors under such conditions [13, 14].
Many stem cells rely heavily on aerobic glycolysis
instead of the TCA cycle to produce ATP. In addition, ROS
production is relatively low due to low OXPHOS; stem
cells are sensitive to ROS, and either die or differentiate
under excessive ROS [18, 19]. TICs from different
types of cancers exhibit higher glycolysis levels than
non-TICs [20, 21]. Also similar to TICs, the metabolic
switch from OXPHOS to aerobic glycolysis regulates the
reprogramming of somatic differentiated cells into induced
pluripotent stem cells (iPSCs) [18, 19].
The above findings suggest a connection between
TICs and metabolic reprogramming; however, the
significance of this connection is still unclear. Here
we show that elevated levels of phosphoenolpyruvate
carboxykinase isoform 2 (PCK2) are critical for the
metabolic switch and maintenance of TICs in prostate
cancer. TIC-enriched clones expressed a high level of
PCK2, and PCK2 knockdown resulted in low numbers
of TICs. In contrast, PKM2 knockdown resulted in
high TICs. Prostate cancer patient database information
revealed that higher levels of PCK2 expression were
associated with more aggressive tumors and lower
survival rates. PCK2 knockdown resulted in low TIC
numbers, increased cytosolic acetyl-CoA and cellular
protein acetylation. Our data suggest PCK2 regulates
tumor initiation of prostate cancer cells by reducing the
mitochondrial tricarboxylic acid (TCA) cycle activity and
thereby production of citrate and acetyl-CoA. Our findings
suggest that PCK2 is critical for the metabolic switch in
tumor initiation, and that PCK2 is a potential therapeutic
target for aggressive prostate tumors.

into two types based on their E-cadherin expression
(Supplementary Figure 1B), and we have used PC3/M-EL
to designate the high E-cadherin expressers and PC3/MML to denote the low E-cadherin clones.
The cell status has been reported to be tightly
related to TICs. Although many TICs have been found
to have mesenchymal characteristics and epithelialmesenchymal transition (EMT) can produce TICs in some
cancer types [24, 25], there are also reports about TICs
enriched in epithelial cell [24]. For example, cells with
high expression of E-cadherin are reported enriched TICs
in prostate cancer cells [26, 27]. Indeed, we found that
the clones that highly expressed E-cadherin (Du145-EL
and PC3/M-EL) contained many more CD44+/CD24prostate cancer TICs [28, 29] than the E-cadherin-low
clones (Du145-ML and PC3/M-ML) (Figures 1F and
Supplementary Figure 1D). To further characterize the
TICs, we examined the clones’ sphere-forming capacity
[30]. Du145-EL cells had a strong sphere-forming ability,
both in the first and second generations (Figures 1A, 1D,
and 1E), compared to the parental and Du145-ML cells.
A similar result was found for the clones derived from
PC3/M: PC3/M-EL cells formed many more spheres than
PC3/M-ML cells (Supplementary Figure 1A and S1C).
We next examined the tumor-initiating ability of
these cells using in vivo xenograft assays. Du145-EL
cells showed a much stronger tumor-initiating ability in
nude mice than Du145-ML cells. Eight weeks after cell
injection, 100% of the mice (5 out of 5) in the Du145-EL
group grew tumors, while only 40% (2 out of 5) in the
Du145-ML group did (Figure 1G), and the Du145-MLderived tumors were significantly smaller (Figure 1H and
1I) and had a longer latency (Figure 1G) than the Du145EL-derived ones.
Thus, the heterogeneous subclones were stable, and
the EL clones, which were enriched in prostate cancer
TICs, showed more aggressive characteristics than the
ML clones.

RESULTS
Isolation of TIC-enriched subclones of prostate
cancer cell lines

Enhanced glycolysis in TIC-enriched prostate
cancer cells

Heterogeneous subclones can be isolated from
prostate cancer cell lines by culturing single-cell clones
[22, 23]. Using this method, we isolated several subclones
from two prostate cancer cell lines, Du145 and PC3/M.
These clones could be stably subcultured (data not shown).
Most of the subclones from Du145 could be divided into
two major types based on their morphology: mesenchymal
or epithelial-like (Figure 1A). We randomly picked one
clone of each type for further analysis. Consistent with
their morphologies, clone D18 (epithelial-like, hereafter
Du145-EL) showed significantly higher E-cadherin
expression than the parental cells or the mesenchymallike clone B2 (hereafter Du145-ML) (Figure 1B and
1C). Although a similar morphological difference was
not observed between the single-cell PC3/M subclones
(Supplementary Figure 1A), they could also be divided
www.impactjournals.com/oncotarget

During daily cell culture, we noticed that the Du145EL cell culture medium has a more acidic appearance than
that of the Du145 parental and Du145-ML cell cultures
(Figure 2A). A change in culture medium color indicates a
change in its pH. We therefore cultured the same number
of Du145 parental, Du145-EL, and Du145-ML cells in
complete medium, and found that the medium from the
Du145-EL cells had a lower pH than that from the other
two (Figure 2B). This finding indicated that the cells had
enhanced glycolysis, or increased glucose consumption
and lactate production/secretion. Therefore, we measured
the glucose consumption and lactate production, and
found they were significantly elevated in the Du145-EL
cells compared to the Du145 parental and Du145-ML cells
83603
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(Figure 2C and 2D). The high glucose consumption in the
Du145-EL cells led us to analyze the cells’ dependence
on glucose for survival. Most Du145 parental and Du145ML cells survived two days of glucose deprivation, most
Du145-EL cells died under the same condition (Figure
2E and 2F), showing that the EL cells were intolerant of
glucose deprivation. We also examined the response of the

three cell groups to glutamine deprivation and found no
significant differences between them (Figure 2E and 2F).
Although the PC3/M-EL and PC3/M-ML cells did
not show significant differences in medium color or pH
(data not shown), the PC3/M-EL cells showed greater
glucose consumption and lactate production than the PC3/
M-ML cells (Supplementary Figure 2A and 2B).

Figure 1: Isolation and characterization of a TIC-enriched single-cell clone from Du145 cells. (A) Morphology of the

Du145 parental cells, Du145-ML clone, and Du145-EL clone (upper), and the first spheres cultured from these cells (bottom). Scale bar,
100 μm. (B and C) E-cadherin expression level in the Du145 parental cells, Du145-ML clone, and Du145-EL clone detected by qPCR and
immunoblotting. (D and E) Numbers of first- and second-generation spheres cultured from the Du145 parental cells, Du145-ML clone,
and Du145-EL clone. (F) Representative flow cytometry results of CD44+/CD24- TICs in the Du145 parental cells, Du145-ML clone, and
Du145-EL clone. (G) Latency of tumor growth in nude mice. (H) Tumor growth over time. Data are the mean ± SEM from five mice. (I)
Tumor weight when the xenograft assay was terminated. Data are the mean ± SEM from five mice. *: p < 0.05.
www.impactjournals.com/oncotarget
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High PCK2 expression in TIC-enriched prostate
cancer cells

the citric acid cycle to various biosynthetic processes,
especially the synthesis of serine, glycerol, and nucleotides
[31]. Using Q-PCR, Western blot, and immunofluoresence
staining, we confirmed the elevated expression of PCK2 in
Du145-EL cells (Figures 3A, 3B, and 3C). We also found
that the PCK2 expression in PC3/M-derived clones was
similarly elevated in the EL cells (Supplementary Figures
3A and 3B).
We next examined the PCK2 expression in clinical
prostate cancer samples. Using published prostate
cancer microarray datasets, we found a much higher
PCK2 expression in metastatic prostate cancer samples
compared to normal tissue or primary cancer tissue in two
datasets (GDS1439 and GDS2524) (Figure 3D and 3E),
indicating that PCK2 is highly expressed in aggressive
prostate cancer. We then analyzed the correlation of
PCK2 expression with patient survival in two independent
cohorts (GSE20134 and GSE16560), and found that, in
both cohorts, patients with high PCK2 expression showed
a lower survival rate (Figure 3F and 3G).

To understand the molecular basis for the glycolytic
switch in the TIC-enriched cells, we first examined the
PKM2 expression in our clones, because enhanced PKM2
expression is associated with the glycolytic switch in
cancer cells [6]. However, we did not find elevated PKM2
expression in the EL clones (Supplementary Figure
2C), suggesting increased PKM2 expression was not
responsible for their change in glucose metabolism.
To find genes responsible for this change, we
compared the gene expression profiles of Du145EL and Du145-ML cells using a microarray assay
(GSE76470). Among the differentially expressed genes,
the gene encoding PCK2, the mitochondrial form of
phosphoenolpyruvate carboxykinase, was greatly elevated
in the EL-clone cells. PCK2 catalyzes the conversion of
oxaloacetate (OAA) to phosphoenolpyruvate (PEP) and
is a key enzyme in the feeder reactions of carbon from

Figure 2: Enhanced glycolysis in TIC-enriched prostate cancer cells. (A) Culture medium color of the Du145 parental cells,

Du145-ML clone, and Du145-EL clone. (B) pH of culture medium from the Du145 parental cells, Du145-ML clone, and Du145-EL clone.
(C) Glucose consumption in the Du145 parental cells, Du145-ML clone, and Du145-EL clone. (D) Lactate production by the Du145
parental cells, Du145-ML clone, and Du145-EL clone. (E) Cell viability detected by crystal violet staining after two days of glucose
deprivation (W/O Gluc) or glutamine deprivation (W/O Gln). FM: full medium. (F) Quantification of cell viability after two days of glucose
deprivation (W/O Gluc) or glutamine deprivation (W/O Gln). FM: full medium. *: p < 0.05; **: p < 0.01.
www.impactjournals.com/oncotarget
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PCK2 is critical for the glycolytic switch in TICenriched cells

virally transfected with a scrambled sequence (Figure 4B
and 4C). We also knocked down PCK2 in PC3/M-EL cells
using the more efficient PCK2i-1 (Supplementary Figure
3C), and again found reduced glucose consumption and
lactate production (Supplementary Figures 3D and 3E).
We next used the stable isotope-resolved
metabolomics (SIRM) approach [32, 33] to analyze
the metabolic fate of U-13C6-glucose in the Du145-EL
scramble and PCK2i-1 cells. GS-MS was used to quantify
13
C-labeled metabolites involved in glycolysis and the
TCA cycle. Consistent with the results we obtained using
unlabeled experiments, the SIRM results showed a trend
of lower glucose consumption and lactate production in
the PCK2-knockdown cells compared to the controls
(Figures 4E). We also found significant increases in 13C2
(M2)-citrate, malate, aspartate (markers of the TCA cycle’s

Considering PCK2’s regulation of OAA and PEP,
we next examined whether PCK2 was responsible for the
change in glucose metabolism in TIC-enriched EL cells.
We used two shRNAs (PCK2i-1 and PCK2i-2) to knock
down PCK2’s expression in Du145-EL cells. PCK2i-1
almost completely blocked and PCK2i-2 dramatically
reduced the PCK2 expression (Figure 4A). Consistent
with the reported function of PCK2, knocking down PCK2
significantly reduced cellular PEP level (Supplementary
Figure 4). We then measured the glucose consumption
and lactate production in the PCK2-knockdown cells
(PCK2i-1 or PCK2i-2), and found that both processes
were decreased compared with control cells that were

Figure 3: PCK2 is highly expressed in TIC-enriched prostate cancer cells and is a prognostic indicator for prostate
cancer patients. (A and B) PCK2 expression in the Du145 parental cells, Du145-ML clone, and Du145-EL clone by qPCR and

immunoblotting. (C) PCK2 expression (green) in the Du145 parental cells, Du145-ML clone, and Du145-EL clone by immunofluorescence
staining. Scale bar, 50 μm. (D and E) PCK2 expression in different subtypes of clinical prostate cancer samples. (F and G) Kaplan-Meier
survival curves for prostate cancer patients grouped according to PCK2 expression. **: p < 0.01.
www.impactjournals.com/oncotarget
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Figure 4: PCK2 is responsible for the reprogramming of glucose metabolism in TIC-enriched prostate cancer cells.

(A) PCK2 knockdown efficiency in Du145-EL cells, as detected by immunoblotting. (B) Glucose consumption in scramble control and
PCK2-knockdown Du145-EL cells. (C) Lactate production by scramble control and PCK2-knockdown Du145-EL cells. (D) Diagram
showing the expected 13C (red and green closed circle) labeling patterns of glycolytic and TCA cycle metabolites derived from 13C6glucose. The TCA cycle reactions depicted represent PDH (red) or anaplerotic PCB-initiated (green) cycle activity for one cycle turn. PDH:
pyruvate dehydrogenase; PCB: pyruvate carboxylase; ACLY: ATP-citrate lyase. (E) 13C6-Glucose uptake and 13C3-lactate production were
determined by GC-MS analysis of the medium of Du145-EL scramble and PCKi-1 cells grown in 13C6-Glucose (mean ± SEM in triplicate).
(F to J) 13C-labeled glycolytic and TCA cycle metabolites determined by GC-MS analysis. Data are the mean ± SEM of triplicate samples.
Doubly and triply 13C labeled citrate are respectively unique markers of PDH and PCB-initiated TCA cycle activity (cf. diagram in D). M0
to m6 refer to mass isotopologues of TCA cycle metabolites with 0 to 6 13C atoms. (K) Quantification of cell viability after two days of
glucose deprivation (W/O Gluc). **: p < 0.01.
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first round),13C3-citrate (marker of pyruvate carboxylation)
and 13C4 (M4)-citrate (marker of the TCA cycle’s second
round) (Figures 4F, 4G, 4H, and 4I). These results further
indicated that PCK2 can remodel the glucose metabolism
in TIC-enriched prostate cancer cells, by enhancing
glycolysis and reducing the TCA cycle.
We then examined the sensitivity of PCK2knockdown cells to two days of glucose deprivation, and
found that the PCK2 knockdown partially rescued the cell
death caused by glucose deprivation in both Du145-EL
cells (Figure 4J) and PC3/M-EL cells (Supplementary
Figure 3F).

knockdown in Du145-EL cells did not significantly affect
the cells’ tumorigenicity in nude mice (Figure 5L, 5M, and
5N). These results suggest that PKM2 is not important for
the maintenance of TICs in prostate cancer.

PCK2 and PKM2 affect TICs by differentially
regulating the ROS status
Our SIRM results also revealed an accumulation
of reduced glutathione (GSH) and total 13C-labeled
glutathione (GSH/GSSG) in the Du145-EL PCK2i-1
cells (Figures 6A). The latter suggest enhanced de novo
glutathione synthesis by PCK knockdown. Glutathione
is one of the major intracellular defenses against ROS
[35], altered glutathione level and synthesis in Du145EL PCK2i-1 cells indicated a change in ROS status. Two
major intracellular ROS are hydrogen peroxide (H2O2)
and superoxide (O2·-), both of which are important for
regulating the growth, survival, and maintenance of TICs
[36]. As glutathione primarily reacts with H2O2, we first
analyzed the H2O2 level with a specific probe, 2', 7’–
dichlorofluorescin diacetate (DCFH-DA). Surprisingly,
we found only a slight, non-significant decrease in the
DCFH-DA signal in Du145-EL PCK2i-1 cells (Figure 6B
and 6C). Since GSH level also increased in Du145-EL
PCK2i-1, it is possible that PCK suppressed cells have
less need for GSH for H2O2 removal. As H2O2 is largely
derived from O2·-, we next examined the intracellular
O2·- level with a specific superoxide detection probe,
dihydroethiodium (DHE) and found that the O2·- level was
significantly higher in the PCK2-knockdown Du145-EL
cells (Figure 6D and 6E).
An increase in ROS is reported to decrease the TICs
in cancer cells [37]. To examine whether the increased
O2·-, rather than H2O2, level in PCK2-knockdown cells
was responsible for the TIC reduction, we treated the
cells with two ROS scavengers, N-acetylcysteine (NAC)
and TempoL. NAC acts as a synthetic precursor to
glutathione synthesis, to enhance glutathione production
and reduce the H2O2 level. NAC treatment did not rescue
the TIC reduction phenotype in PCK2-knockdown cells
(data not shown), which is consistent with the observed
accumulation instead of depletion of GSH in these cells.
However, treating the cells with TempoL, an O2·--specific
scavenger, significantly increased the proportion of TICs
(TIC ratio) (Figure 6F). Furthermore, knocking down
PCK2 in PC3/M-EL cells also induced a significant
increase in O2·-, and TempoL rescued the TIC ratio in
these cells (Supplementary Figure 6A, 6B, 6C, 6D, and
6E). However, increased H2O2 level was evident in PCK2
suppressed PC3/M-EL cells, unlike PCK2 knockdown
Du145-EL cells. These results suggest that PCK2 can
modulate TICs in TIC-enriched prostate cancer cells via
regulating cellular ROS, particularly the O2·- level.
Because PKM2 knockdown increased the TICs in
prostate cancer clones, we also examined the ROS level in

PCK2 and PKM2 differentially regulate TICs in
prostate cancer cells
To analyze whether PCK2 regulates the TIC
characteristics of prostate cancer cells, we determined the
number of TICs in PCK2-knockdown clones using flow
cytometry. PCK2 knockdown using PCK2i-1 and PCK2i-2
reduced CD44+/CD24- TICs in the TIC-enriched Du145EL cells by over 80% and 50%, respectively (Figure 5A
and 5B). A similar result was observed in PC3/M-EL cells
treated with PCK2i-1 (Supplementary Figure 5A and 5B),
albeit less in extent for the reduction of CD44+/CD24TICs. We also confirmed that the sphere-forming ability
was significantly inhibited when the PCK2 expression
was down-regulated in Du145-EL (Figure 5C and 5D)
and PC3/M-EL (Figures S5C and S5D) cells. Consistent
with our other findings, when the Du145-EL scramble
control and PCK2i-1 cells were subcutaneously injected
into nude mice and the xenograft growth was measured
weekly, tumors derived from the PCK2-knockdown cells
were significantly smaller than those derived from the
scramble control (Figure 5E, 5F and 5G).
Although we did not find a significant difference
in PKM2 expression between our ML and EL clones,
because PKM2 is reported to have important roles of
glycolytic control in cancer cells, we further analyzed
its regulation of TICs in our system. We knocked down
the PKM2 expression using a specific shRNA construct
in both Du145-EL (Figure 5H) and PC3/M-EL cells
(Supplementary Figure 5E). Consistent with previous
reports [6], PKM2 knockdown significantly reduced
glucose consumption and lactate production in both types
of cells (Figures 5I, 5J, Supplementary Figure 5F, and
5G), and accumulated PEP (Supplementary Figure 4).
We then analyzed the TICs by measuring the CD44+/
CD24- subpopulation using flow cytometry. Surprisingly,
in contrast to the effect of PCK2 knockdown, the downregulation of PKM2 significantly increased the CD44+/
CD24- TICs in both clones (Figures 5K, Supplementary
Figure 5H, and 5I). This finding was inconsistent with
previous reports showing that PKM2 knockdown can
block the tumorigenicity of lung cancer and glioma
cells [6, 34]. Interestingly, we also found that PKM2
www.impactjournals.com/oncotarget
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PKM2-knockdown cells. Unlike the PCK2 knockdown,
PKM2 knockdown did not affect the O2·- level in Du145EL cells (Figure 6D and 6E). However, the H2O2 level
was dramatically decreased in the PKM2i cells (Figure
6B and 6C). These results are consistent with a previous
finding that inhibiting PKM2 activity can enhance the

PPP and reduce the H2O2 level in lung cancer cells [11].
We therefore treated the cells with 6-aminonicotinamide
(6-AN), a specific inhibitor for 6-phosphogluconate
dehydrogenase, the first enzyme in the PPP. This
treatment significantly decreased the proportion of TICs
in the Du145-EL PKM2-knockdown cells (Figure 6G),

Figure 5: PCK2 and PKM2 differentially regulate TICs in prostate cancer cells. (A) Representative flow cytometry results

of CD44+/CD24- TICs in scramble control and PCK2-knockdown Du145-EL cells. (B) Quantification of CD44+/CD24- TICs in scramble
control and PCK2-knockdown Du145-EL cells. (C) Representative sphere formation results from scramble control and PCK2-knockdown
Du145-EL cells. Scale bar: 50 μm. (D) Quantification of spheres in scramble control and PCK2-knockdown u145-EL cells. (E) Du145-EL
scramble and PCK2i-1 cells were injected into nude mice. Tumor volume was monitored weekly. Data are the mean ± SEM from five mice.
(F) Tumors derived from Du145-EL scramble and PCK2i-1 cells. (G) Tumor weight when the xenograft assay was terminated. Data are the
mean SEM from five mice. (H) PKM2 knockdown efficiency in Du145-EL cells, as detected by immunoblotting. (I) Glucose consumption
in scramble control and PKM2-knockdown Du145-EL cells. (J) Lactate production by scramble control and PKM2-knockdown Du145-EL
cells. (K) Quantification of CD44+/CD24- TICs in scramble control and PKM2-knockdown Du145-EL cells. (L) Du145-EL scramble and
PKM2i cells were injected into nude mice. Tumor volume was monitored weekly. Data are the mean ± SEM from five mice. (M) Tumors
derived from Du145-EL scramble and PKM2i cells. (N) Tumor weight when the xenograft assay was terminated. Data are the mean ± SEM
from five mice. *: p < 0.05; **: p < 0.01.
www.impactjournals.com/oncotarget
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Figure 6: PCK2 and PKM2 differentially regulate cellular ROS. (A) Representative HSQC NMR spectra showing the changes

in 13C abundance (represented by the intensity of 13C-attached 1H peaks) of various assigned metabolites in the Du145-EL scramble (Scr,
black) and PCK2i-1 (PCKi, red) cells. Also shown is the bar graph of average levels of 13C labeled glutathiones (Gluta, GSH+GSSG) and
their precursors Gly and Glu; data are represented as mean ± SEM in triplicate. (B) Representative flow cytometry results of the H2O2
level detected by DCFH-DA staining in the scramble control, and PCK2- and PKM2-knockdown Du145-EL cells. (C) Quantification of
the H2O2 level in the scramble control, and the PCK2- and PKM2-knockdown Du145-EL cells. MFI: mean fluorescence intensity, **: p <
0.01 (compared to scramble control). (D) Representative flow cytometry results of the O2·- level detected by DHE staining in the scramble
control, and the PCK2- and PKM- knockdown Du145-EL cells. (E) Quantification of the O2·- level in the scramble control, and the PCK2and PKM2-knockdown Du145-EL cells. MFI: mean fluorescence intensity, *: p < 0.05 (compared to scramble control). (F) Quantification
of CD44+/CD24- TICs in the scramble control and PCK2-knockdown Du145-EL cells after 1 mM TempoL treatment for 2 days. (G)
Quantification of CD44+/CD24- TICs in the scramble control and PKM2-knockdown Du145-EL cells after 10 μM 6-AN treatment for 2
days. (H) HSQC NMR uantification of 13C labeled ribose moiety of adenine nucleotides (AXP) and uracil nucleotides (UXP) in Du145EL Scramble and PCK2i-1 cells, data are represented as mean ± SEM in triplicate. The ribosyl unit of AXP and UXP is derived from the
pentose phosphate pathway (PPP). (I and J) GC-MS quantification of 13C labeled serine and glycine in Du145-EL Scramble and PCk2i-1
cells, data are represented as mean ± SEM in triplicate. M0 to m3 refer to mass isotopologues of Gly or Ser with 0 to 3 13C atoms. *: p <
0.05; **: p < 0.01.
www.impactjournals.com/oncotarget
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indicating that the increase in TICs in PKM2-knockdown
cells was partially due to the elimination of intracellular
ROS through the PPP.

these cells (Figure 7H). Together, these results indicate
that modulation of cellular acetyl CoA level and protein
acetylation is an important factor in PCK2’s ability to
maintain TICs in prostate cancer cells.

PCK2 regulates TICs by modulating cellular
acetylation

DISCUSSION

Two major pathways related to glucose metabolism
that are important in regulating tumorigenicity are
the PPP and the serine/glycine synthesis pathway [8,
9, 11]. However, our SIRM results indicated a slight
enhancement, rather than attenuation of these two
pathways in the Du145-EL PCK2i-1 cells (Figures 6H, 6I
and 6J), indicating that some other mechanism must be
involved in the PCK2-regulated TIC maintenance.
When analyzing the SIRM results, we noticed a
small increase of 13C-acetate (product of acetyl CoA) level
in PCK2i-1 cells (Figure 7B), in addition to increased
production of 13C-citrate (precursor to cytoplasmic acetyl
CoA) (Figure 4D). These data point to an enhanced acetyl
CoA production from citrate in the cytoplasm via the ATP
citrate lyase (ACLY) action. Consistent with the SIRM
results, the acetyl-CoA was also significantly increased in
PCK2i cells (Figure 7C).
Given that acetyl-CoA is a major regulator of
protein acetylation [12, 17], and protein acetylation
regulates cancer cell proliferation, survival, and even TIC
maintenance [38, 39], we examined protein acetylation in
the PCK2-knockdown cells. Consistent with the increase
in acetyl-CoA, the Du145-EL PCK2i-1 and PCK2i-2
cells showed enhanced acetylation in both whole-cell
lysates and acid-extracted histones (Figure 7D and 7E).
We also performed immunofluorescence staining, using
an anti-acetylated lysine antibody, and found enhanced
cytoplasmic staining of acetylated lysine in the Du145EL PCK2i-1 cells (Supplementary Figure 7A). We then
examined whether this enhanced acetylation was due to
the increased acetyl-CoA production via ATP citrate lyase
(ACLY) (Figure 7) in PCK2-knockdown cells. Since
ACLY’s production of cytoplasmic acetyl-CoA promotes
protein acetylation [17], we treated the PCK2-knockdown
cells with an ACLY-specific inhibitor, SB204990. This
treatment dramatically reduced acetylation in the PCK2knockdown cells (Figure 7F).
Since knocking down PCK2 reduced TICs in
prostate cancer cells, we then asked whether this is
related to cellular acetylation change. To mimic the
enhanced acetylation in PCK2-knockdown cells, we
treated Du145-EL cells with class I and class II histone
deacetylase (HDAC) inhibitors, SAHA and CI994. SAHA
and CI994 significantly reduced the TICs in Du145-EL
cells (Figure 7G and 7B). We then examined whether
inhibiting acetylation could rescue the TIC reduction in
PCK2-knockdown cells. SB204990 treatment, which
dramatically reduced the acetylation in PCK2 knockdown
cells, also significantly increased the number of TICs in
www.impactjournals.com/oncotarget

In this study, we grew up subclones from single cells
of heterogeneous prostate cancer cell lines to obtain TICenriched and TIC-impoverished clones. We analyzed the
clones’ CD44+/CD24- markers, in vitro sphere formation,
and tumor formation in xenograft mice. We uncovered
several important aspects of metabolic reprogramming
and TIC maintenance in tumorigenesis. First, we found
that selected TIC-enriched prostate cancer cell clones use
more glucose and secrete more lactate than their TIC-low
counterparts.Second,we determined that PCK2 is critical
for the metabolic switch that generates and maintains
TICs in prostate cancer. Third, we found that PCK2 and
PKM2 have opposite roles in regulating TICs and ROS
production. Fourth, PCK2 knockdown resulted in reduced
TCA cycle and thereby lower citrate, cytosolic acetylCoA and cellular protein acetylation. Our data suggest
that by shunting anion OAA as PEP from mitochondria
to the cytosol PCK2 regulates tumor initiation of prostate
cancer cells through reducing the TCA cycle, ROS level,
and production of citrate and acetyl-CoA. Finally, using
patient databases, we found that higher PCK2 expressions
are associated with more aggressive tumors and lower
survival rates in prostate cancer patients. Thus, PCK2 is a
potential therapeutic target for aggressive prostate tumors.

Compare PCK2 and PKM2 in regulating
glycolytic reprogramming and TICs
PCK catalyzes the conversion of OAA to PEP
[31]. It has two isoforms, a cytoplasmic form (PCK1,
PEPCK-C) and a mitochondrial isoform (PCK2,
PEPCK-M). PCK2 is a cataplerotic enzyme that can
directly shunt excess citric acid cycle anion OAA as PEP
from mitochondria to the cytosol. It was recently reported
that PCK2 is highly expressed in different cancer cells and
samples [40, 41]. A recent study also found that PCK2
can regulate TICs in melanoma cells [42]. However, PCK2
has been found to be downregulated in TICs in melanoma
cells and repressed their tumorigenic ability. Opposite
to those findings in melanoma, we found that PCK2
was upregulated in more aggressive prostate tumors and
elevated PCK2 levels enriched TICs.
Recent studies have highlighted the importance of
the biosynthetic and metabolic pathways of serine and
glycine in cancer [43]. Serine and glycine are important
components in the anabolic building blocks for the
generation of glutathione, nucleotides, phospolipids, and
other metabolites. PHGDH, the first enzyme of the de
novo serine synthesis pathway, was found to be amplified
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in both breast cancer and melanoma [9, 10]. It was
demonstrated that the pathways of aerobic glycolysis and
the biosynthesis of serine and glycine are interconnected
through PKM2 [44, 45]. Pyruvate kinase catalyzes the final
step in glycolysis by transferring the phosphate from PEP

to ADP, thereby generating pyruvate and ATP. Cancer cells
selectively express the less active M2 isoform of pyruvate
kinase (PKM2) [6]. Serine can bind to and activate PKM2.
In a condition of serine deprivation, PKM2 activity was
low, which would result in the accumulation of glycolytic

Figure 7: PCK2 regulates TIC maintenance by modulating protein acetylation via the citrate-pyruvate shuttle. (A)

Diagram showing the production of cytosolic acetyl-CoA by ACLY. (B) Quantification of 13C-acetate level in Du145-EL scramble and
PCK2i-1 cells from HSQC NMR results, data are represented as mean ± SEM in triplicate. (C) Quantification of acetyl-CoA in Du145-EL
scramble and PCK2-knockdown cells. *: p < 0.05. (D) Cellular acetylation level detected by western blotting in cell lysates of scramble
control and PCK2-knockdown Du145-EL. Short (left) and longer (right) exposures were used to show the differences. * indicates bands that
were different between the scramble and PCK2-knockdown cells. (E) Histone acetylation detected by western blotting in acid-extracted
histone samples from scramble control and PCK2-knockdown Du145-EL cell lysates. (F) Cells were treated with 100 μM SB204990 for
2 days, then the acetylation level was detected by western blotting in cell lysates. Short (left) and longer (right) exposures were used to
show the differences. * indicates bands that were different between the scramble and PCK2-knockdown cells. (G) Quantification of CD44+/
CD24- TICs in Du145-EL cells after 2 μM SAHA or 10 μM CI994 treatment for 2 days. (H) Quantification of CD44+/CD24- TICs in
scramble control and PCK2-knockdown Du145-EL cells after 100 μM SB204990 treatment for 2 days. **: p < 0.01.
www.impactjournals.com/oncotarget
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metabolites (such as PEP) and the channeling of them into
the serine biosynthesis to support cell proliferation [44, 45].
PCK2 directly shunts OAA as PEP from
mitochondria to the cytosol; therefore both high PCK2
level and low PKM2 activity should result in accumulation
of PEP and enhance serine biosynthesis to support cell
proliferation. We found that the TIC-enriched clones
express a high level of PCK2, and knocking down PCK2
significantly reduced CD44+/CD24- TICs in the TICenriched clones Du145-EL and PC3/M-EL; however,
downregulation of PKM2 significantly increased CD44+/
CD24- TICs in both clones. This is consistent with the
potential functions of PKM2 and PCK2 in serine synthesis.
Both the reduction of PKM2 activity and the elevation
of PCK2 activity are support to channel more carbon
through the TCA cycle to serine synthesis. However, our
SIRM results indicated a slight enhancement, rather than
attenuation of the PPP and the serine/glycine synthesis
pathway in the Du145-EL PCK2i-1 cells (Figures 6H,
6I and 6J), indicating that the serine/glycine synthesis
pathway may be not involved in the PCK2-regulated TIC
maintenance. We further found that PCK2 knockdown
resulted in reduced TCA cycle and thereby lower citrate,
cytosolic acetyl-CoA and cellular protein acetylation.
Therefore, PCK2 and PKM2 regulate TICs by distinct
mechanisms. The reduction of PKM2 activity may
channel more carbon through PEP to serine synthesis for
increasing TICs, while the elevation of PCK2 activity will
enrich TICs through reducing the TCA cycle, ROS level,
and production of citrate and acetyl-CoA.
Consistent with our above observation, it has
been noted that pluripotent stem cells primarily utilize
glycolysis for their energy supply, while the differentiated
cells rely on OXPHOS [18, 19]. Mitochondria, the central
organelles in most cells, are the main sites for converting
the final metabolites of carbohydrate, and lipid and amino
acid to ATP and reactive oxygen species (ROS) through
the OXPHOS processes by consuming O2 in the TCA
cycle. However, the mitochondria in human and mouse
embryonic stem cells are underdeveloped (a small number
of rounded and non-fused cristae), while mitochondria in
haematopoietic stem cells (HSCs) are relatively inactive.
But after bone marrow damage, HSCs undergo rapid
differentiation, and robust mitochondrial metabolism
supplies the energy and ROS for this transition. In addition,
many stem cells, including HSCs and mesenchymal stem
cells reside in a hypoxic niche in vivo and are quiescent.
They are generally sensitive to ROS. Excessive ROS
induces either death or differentiation of stem cells. A
lower level of ROS is critical for self-renewal of HSCs
and CSCs in some human and murine breast tumors [37].
Together, these data suggest that stem cell metabolism
can be reprogrammed on the basis of functional demands.
Self-renewing stem cells rely mainly on aerobic glycolysis
to maintain their quiescent state to ensure life-long
tissue renewal capacity, but they have to rapidly switch
www.impactjournals.com/oncotarget

to mitochondrial OXPHOS to meet the robust energy
demands associated with differentiation [18, 19].

PCK2 maintains TICs by reducing cellular
acetyl-coA
In both yeast and many mammalian cells, elevated
levels of acetyl-CoA are associated with cell growth
[12–15]. The increased acetyl-CoA induces acetylation of
histones on a set of more than 1,000 genes important for
ribosome biogenesis, protein translation, and amino acid
biosynthesis. Our metabolic characterization of PCK2
knockdown in prostate cancer cells found that knocking
down PCK2 resulted in acetyl-CoA accumulation,
increased protein acetylation, and dramatically reduced
the proportion of TICs. Inhibiting acetylation with an
ATP citrate lyase (ACLY)-specific inhibitor, SB204990,
dramatically reduced acetylation and increased the number
of TICs in the PCK2-knockdown cells (Figure 7). Our
data suggest that PCK2 promotes tumor initiation through
lowering acetyl-CoA level by shunting anion OAA as PEP
from mitochondria to the cytosol and thereby reducing the
TCA cycle.
There are two possible explanations for the
appearing inconsistence between the published
information and our result. First, decreased protein
acetylation has been reported in some cancer cells, and
increasing protein acetylation by inhibiting deacetylases
such as histone deacetylases (HDACs) and NAD+dependent sirtuin deacetylases (SIRTs), can inhibit certain
cancer cells and CSC/TIC growth [46, 47]. Second, TICs
are resistant to both radiation and chemotherapy (mostly
targeting growing cells) in conventional treatments [3, 4,
48], such treatments enrich TICs in tumors and endowing
them with more aggressive characteristics. TICs are
relatively quiescent cells; poor conditions for growth
(such as low acteyl-CoA) may favor their enrichment. Our
results suggest that targeting tumors by lowering acetylCoA procedures may have the risk to enrich TICs.

PCK2 is a potential therapeutic target for
aggressive tumors
In the past few years, metabolic reprogramming
has been rediscovered as a driving force of tumorigenesis
and used as a new hallmark for cancer [49]. This finding
has raised the new and exciting expectation that targeting
metabolic enzymes, such as PKM2, may offer unique
opportunities in cancer treatment [50]. Most tumor cells
express relatively less active PKM2 dimers, and the lower
PKM2 activity promotes the accumulation of upstream
glycolytic intermediates, which are channeled into serine
biosynthesis for cell proliferation [44, 45, 50]. Some
small molecular activators of PKM2 are currently under
development to suppress tumor growth by increasing
pyruvate kinase activity [51].
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However, recent findings from PKM2-knockout
mice suggest that there is a differential requirement for
pyruvate kinase activity among tumor cell populations
[50]. Increased pyruvate kinase activity may favor
the survival of some cancer cells, which complicates
therapeutic strategies that target PKM2. Our study suggests
that inhibiting PCK2 may overcome the shortcomings of
targeting PKM2 and may be therapeutically valuable for
cancers with elevated PCK2 expression. Elevated PCK2
has been reported in lung cancer cell lines, non-small cell
lung cancer samples, and other types of cancer cells [40,
41]. In prostate cancer patients, high PCK2 is detected
in more aggressive tumors, and patients with high PCK2
expression have lower survival rates. These findings
indicate that PCK2 may play an important role in prostate
cancer progression. Notably, we found that knocking
down PCK2 could significantly reduce the proportion of
TICs in prostate cancer cells, indicating that PCK2 is a
potential target for therapies against TICs.

F: 5’- ACCAGAATAAAGACCAAGTGACCA -3’
R: 5’- AGCAAGAGCAGCAGAATCAGAAT -3’
PCK2:
F: 5’- CATCCGAAAGCTCCCCAAGT -3’
R: 5’- GCAGCCTGGAAACCTCTCAT -3’

Gene microarray
Gene microarray assay was performed in Advanced
Technology Research Facility at the NCI at Frederick,
Frederick, MD, USA. Briefly, total RNA was extracted
from DU145-ML and DU145-EL cells using the RNeasy®
Mini Kit (Qiagen), according to the manufacturer's
instructions. Qualified RNA was hybridized on Affymetrix
human gene ST 1.0 microarrays. After scanning and
normalization, the microarray data were analyzed by
Partek Genomics Suite 6.6.

Immunoblotting and immunofluoresence
staining

MATERIALS AND METHODS

Cells were washed twice with PBS and lysed in
RIPA buffer. Protein concentrations were quantified
using the Bradford reagent (Bio-Rad) according to the
manufacturer's instructions. Samples with equal amounts
of protein were separated by 4%–15% SDS-PAGE,
then transferred to an Immobilon transfer membrane
(Millipore) and immunoblotted with specific antibodies
against E-cadherin, PCK2, PKM2, and Acetylated-Lysine
(Ac-K2-100, #9814) from Cell Signaling, and GAPDH
from Thermo Scientific. All of the immunoblots were
visualized by enhanced chemiluminescene (Bio-Rad).
Immunofluoresence staining was performed to
detect PCK2 expression and protein acetylation. Cells
were plated in a 24-well multiwell glass-bottomed culture
plate (MatTek), fixed in 4% formaldehyde in PBS for 15
min at room temperature, and then washed three times
with PBS. After being blocked with PBS containing 5%
goat serum and 0.3% Triton X-100 at room temperature
for 1 h, the cells were incubated overnight with antiPCK2 primary antibody (1:100, Cell Signaling) or antiacetylated-Lysine (1:200, Cell Signaling #9441) at 4°C.
The secondary antibody, Alexa Fluor 488-conjugated
donkey anti-rabbit IgG (Molecular Probes) was used at
a 1:1000 dilution. Fluorescence was monitored by an
inverted confocal laser microscope (Carl Zeiss).

Cell lines and single-cell clones’ isolation
Human prostate cancer cell lines Du145 and PC3/M
(kindly provided by the DCTD Tumor Repository of
NCI at Frederick, MD) were cultured in RPMI1640
supplemented with 10% fetal bovine serum and 100
units/ml penicillin/streptomycin, at 37°C in a humidified
atmosphere containing 5% CO2.
Single-cell clones were isolated as previously
reported [22, 23]. Briefly, cells were suspended in full
culture medium at ~5 cells/ml, and then dispensed into 96well culture plates at 200 μl/well. Each well was carefully
checked under a phase-contrast microscope after plating.
Wells containing just one cell were marked and checked
daily. Holoclones that grew from the marked wells were
sub-cultured and used for further analysis.

RNA isolation and real-time PCR
Total RNA was extracted from cells using
the RNeasy® Mini Kit (Qiagen), according to the
manufacturer's instructions. Using a reverse transcription
kit (Promega), 1 μg RNA from each sample was processed
directly to cDNA. Amplification was performed in a 15-μL
reaction system using SYBR® Advantage® qPCR Premix
(Clotech). All of the reactions were performed in triplicate
in a Realplex2 system (Eppendorf). The relative gene
expression level was quantified as described previously
[52].
The sequence of each primer was as follows:
Actin:
F: 5’- GATCATTGCTCCTCCTGAGC -3’
R: 5’- ACTCCTGCTTGCTGATCCAC -3’
E-Cadherin:
www.impactjournals.com/oncotarget

Flow cytometry
Cell-surface markers and cellular ROS were
analyzed by flow cytometry. To detect cell-surface
markers, cells were dissociated by 0.05% trypsinEDTA and centrifuged. The cells were resuspended in
PBS containing 2% FBS and fluorescence-conjugated
antibodies, FITC-CD44 (clone G44-26, BD Biosciences)
and PE-CD24 or APC-CD24 (clone ML5, Biolegend), and
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incubated on ice for 30 min. After three washes in PBS
containing 2% FBS, the cells were resuspended in PBS
containing 2% FBS and analyzed by FACSCalibur (BD
Biosciences).
To detect cellular ROS, cells were incubated with
5 ng/ml DCFH-DA (Santa Cruz) or 10 μM DHE (Life
Technologies) at 37°C for 30 min. They were then
dissociated by 0.05% trypsin-EDTA and centrifuged. After
being washed with PBS containing 2% FBS, the cells were
resuspended in PBS containing 2% FBS and analyzed by
FACSCalibur (BD Biosciences).

caliper and calculated using the formula: volume = 0.5 ×
length × width2. The results are presented as the mean ±
SE. All animals used in this research project were cared
for and treated humanely according to the following
policies: the U.S. Public Health Service Policy on Humane
Care and Use of Laboratory Animals (2000); the Guide
for the Care and Use of Laboratory Animals (1996); and
the U.S. Government Principles for Utilization and Care
of Vertebrate Animals Used in Testing, Research, and
Training (1985). All NCI at Frederick animal facilities and
the animal program are accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
International.

Sphere formation assay
Cells were cultured in a Corning® Costar® UltraLow attachment 24-well plate (Sigma-Aldrich) in sphere
culture medium DMEM/F12 (1:1) with B27 (Invitrogen)
and 20 ng/ml EGF (Invitrogen). For Du145 and its derived
clones, new medium was added every three days. For
PC3/M-derived clones, the cells were cultured in the
sphere culture medium for three days, then sphere culture
medium with 0.5% FBS was added every three days. The
spheres were counted after 10 days in culture.

Stable isotope-resolved metabolomic (SIRM)
experiment with 13C6-glucose tracer
Du145-EL scramble (Scr) and PCK2i-1 cells were
cultured in the RPMI1640 medium with 0.2 % unlabeled
or 13C6-glucose for 24 hrs, as described previously [53].
Acetonitrile/water/chloroform (2/1.5/1, v/v) partitioning
method was used to extract polar metabolites from cell
and media. The extracts were subjected to NMR and GCMS analysis as previously described [32].

Glucose, lactate, PEP and acetyl-coA detection

Statistical analysis

The concentration of glucose and lactate in the cell
culture medium and of PEP and acetyl-CoA in cell lysate
was detected by a glucose assay kit (Eton Bioscience),
L-lactate assay kit I (Eton Bioscience), PEP Fluorometric
Assay Kit (Cayman) and the PicoProbe™ Acetyl-CoA
Fluorometric Assay Kit (Biovision), respectively. The
assays were performed as instructed by the manufacturer.

Statistical analysis was performed using SPSS
13.0 for Windows. The data were presented as mean
values ± standard deviation, except those from the in vivo
tumorigenicity assay. Statistically significant differences
were determined by Student’s t-test and one-way ANOVA,
where appropriate, and defined as P < 0.05.

shRNA knockdown of PCK2 and PKM2

Author contributions

The PCK2 shRNA constructs (TRCN0000052666
and TRCN0000052667) were purchased from MISSION
shRNA at Sigma-Aldrich. A PKM2 shRNA construct
(plasmid: 42516) and a scramble control construct
(plasmid: 1864) were purchased from Addgene. The
shRNA constructs were co-transfected with three
lentiviral packaging plasmids into 293T cells. The culture
medium containing lentivirus was harvested two days
after transfection. Cells were infected with the harvested
medium (filtered with 0.45 μm filter) and selected with 1
μg/ml puromycin (Invivogen).

J.Z. and S.H. designed the research. J.Z. performed
most of the experiments and data analysis. T.F. designed
SIRM experiments. J.Z. prepared samples for SIRM
assays. J.L. and T.F. performed assays and data analysis of
SIRM. S.H., T.F. and J.Z. wrote the manuscript.
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